Business
SPECTRAL ACHIEVES IMPORTANT MILESTONE IN ITS PIVOTAL U.S. CLINICAL TRIAL FOR SEPSIS
May 5, 2011 (Canada NewsWire Group) -- - All 15 sites for the EUPHRATES trial are operatio...
About this update from Spectral Medical Inc
[{"type":"text","content":"\n\n\n May 5, 2011 (Canada NewsWire Group) -- \n\n#ReleaseContent TABLE\n{\n BORDER-COLLAPSE: collapse\n}\nTR.cnwUnderlinedCell TD\n{\n BORDER-BOTTOM: #000000 1px solid\n}\nTR.cnwDoubleUnderlinedCell TD\n{\n BORDER-BOTTOM: #000000 3px double\n}\nTR.cnwBoldUnderlinedCell TD\n{\n BORDER-BOTTOM: #000000 3px solid\n}\nTD.cnwUnderlinedCell\n{\n BORDER-BOTTOM: #000000 1px solid\n}\nTD.cnwDoubleUnderlinedCell\n{\n BORDER-BOTTOM: #000000 3px double\n}\nTD.cnwBoldUnderlinedCell\n{\n BORDER-BOTTOM: #000000 3px solid\n}\n#ReleaseContent TABLE.cnwBorderedTable TD\n{\n BORDER-RIGHT: black 1px solid;\n PADDING-RIGHT: 2px;\n BORDER-TOP: black 1px solid;\n PADDING-LEFT: 2px;\n PADDING-BOTTOM: 2px;\n BORDER-LEFT: black 1px solid;\n PADDING-TOP: 2px;\n BORDER-BOTTOM: black 1px solid;\n BORDER-COLLAPSE: collapse\n}\n#ReleaseContent TABLE TD\n{\n PADDING-RIGHT: 2px;\n PADDING-LEFT: 2px;\n PADDING-BOTTOM: 2px;\n PADDING-TOP: 2px\n}\n\n\n- All 15 sites for the EUPHRATES trial are operational and enrolment is\n underway -\n\n\nTORONTO, May 5 /CNW/ - Spectral Diagnostics Inc., (TSX: SDI), a Phase III company developing the first theranostic treatment for \n septic shock, today announced that the 15 carefully chosen clinical\n sites for its EUPHRATES trial are all screening and able to enrol\n patients.\n\n\n"The successful enrolment of patients within these outstanding hospitals\n is indicative of the support for our trial and of the participating\n clinicians' commitment to our novel trial protocol," said Dr. Paul\n Walker, CEO of Spectral Diagnostics. "Once patients have met clinical\n entry criteria, they are tested using Spectral's EAA™ diagnostic and,\n then, those shown to be endotoxemic are treated with a targeted\n therapeutic, Toraymyxin. This is the first time that a theranostics\n approach has been used in a sepsis trial. Having achieved this\n significant milestone, we are looking forward to the interim trial\n results, which we anticipate by the end of the first half of 2012."\n\n\nEUPHRATES is a randomized, double-blind clinical trial that compares\n standard of care versus standard of care and Toraymyxin, directed by\n Spectral's EAA™ Endotoxin Activity Assay. The target population is\n critically ill patients with septic shock and endotoxemia (as measured\n by the EAA™). The trial is expecte...